Blog: Putting 340B Program Growth in Context

Dec 16, 2025 - 03:27 PM
340B pic

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  

“When appropriately contextualized, this data is evidence that the 340B program is one of the most consequential policy solutions to address high and rising drug prices, as well as ensure that drug companies contribute to the health care safety net in communities across this country,” the blog notes. 

The blog discusses how the 340B program has expanded over the years due to policy, market and technological forces — but “of these forces, nothing is more consequential to growth in the 340B program than the high prices drug companies charge for both new and older drugs.” 

The blog also urges policymakers to “protect and preserve the 340B program so it can continue to allow eligible providers to stretch their scarce resources, reach more patients and provide more comprehensive services.” 

Related News Articles

Headline
AHA challenges HRSA’s burden estimate for proposed 340B rebate model
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
AHA urges court to reject AbbVie bid to change 340B program rules
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
HRSA announces 340B program sales reached $100 billion in CY 2025
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…
Perspective
Keeping Patient Access Front and Center in Washington
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
CMS proposes increases to Medicare hospital outpatient department payment rates, site-neutral and 340B changes
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
FDA announces actions to accelerate drug development 
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…